Deadline Boosts Colorectal Cancer Screening Uptake in TEMPO Trial

By João L. Carapinha

March 17, 2025

Are deadlines the secret to increasing colorectal cancer screening rates? The TEMPO trial, a nationwide randomized controlled trial in Scotland, evaluated the impact of two behavioral interventions on colorectal cancer screening uptake. These interventions included adding a deadline for returning faecal immunochemical tests (FIT) and using a problem-solving planning tool. The study found that including a deadline in the invitation letter significantly increased timely FIT returns and reduced the need for reminder letters. The planning tool had no positive effect. A 2-week deadline was identified as the most effective and acceptable option.

Key Insights from the TEMPO Trial

  • Deadline Effectiveness. Adding a deadline to the FIT invitation letter increased timely returns and reduced the need for reminder letters. The 2-week deadline was particularly effective in enhancing colorectal cancer screening rates.
  • Planning Tool Ineffectiveness. The planning tool did not improve FIT return rates and was even detrimental when used without a deadline.
  • Cost-Effectiveness. The deadline intervention is highly cost-effective, requiring minimal additional resources.

Understanding the Colorectal Screening Landscape

Colorectal cancer screening uptake is suboptimal globally, with about 50% participation in European FIT programs. Interventions like deadlines and planning tools could enhance participation. The TEMPO trial is the first to assess these interventions within a nationwide screening program.

Strategic Implications and Future Directions

Implementing deadlines could increase FIT returns and potentially save lives by facilitating earlier detection of colorectal cancer. Reducing reminder letters can lead to substantial cost savings for screening programs. Further studies should explore the effectiveness of deadlines in other screening contexts. They should also assess potential barriers to implementation, such as literacy levels and language barriers. For more insights into the effectiveness of these interventions, you can explore the article on The Lancet’s website here.

Reference url

Recent Posts

NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Surgery

By João L. Carapinha

September 18, 2025

The NICE kidney cancer guideline represents a major shift in how renal cell carcinoma is diagnosed and managed in the UK. How does this guideline change the standard of kidney cancer care? By emphasizing more accurate diagnosis—especially the targeted use of kidney biopsies—it aims to avoid unnec...
CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...